Oncotarget

Research Papers:

RUNX3 regulates hepatocellular carcinoma cell metastasis via targeting miR-186/E-cadherin/EMT pathway

Yuli Gou, Fangbing Zhai, Liang Zhang _ and Lan Cui

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:61475-61486. https://doi.org/10.18632/oncotarget.18424

Metrics: PDF 473 views  |   HTML 1241 views  |   ?  


Abstract

Yuli Gou1,*, Fangbing Zhai2,*, Liang Zhang3 and Lan Cui4

1Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China

2Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China

3Department of Interventional Therapy, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China

4Department of Ophthalmology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China

*These authors have contributed equally to this work as the co-first authors

Correspondence to:

Liang Zhang, email: zhangliangdlmu@163.com

Lan Cui, email: cuilandlmu@163.com

Keywords: RUNX3, miR-186, E-cadherin, HCC

Received: May 04, 2017     Accepted: May 23, 2017     Published: June 09, 2017

ABSTRACT

Runt-related transcription factor 3 (RUNX3) has been reported as a tumor suppressor in some kinds of cancers. In the present study, hepatocellular carcinoma (HCC) microarray analysis showed that RUNX3 expression was significantly lower in HCC tissues compared with that in adjacent non-tumor tissues, and was negatively associated with metastasis and TNM stage. RUNX3 was an independently prognostic factor for 5-year overall and disease-free patient survival. Mechanically, RUNX3 repressed metastasis and invasion of HCC, and increased E-cadherin expression. RUNX3 also repressed microRNA-186 to increase E-cadherin expression. We demonstrated that miR-186 mimics attenuated RUNX3-induced increase of E-cadherin and inhibition of metastasis and invasion. In conclusion, RUNX3 suppressed HCC cell migration and invasion by targeting the miR-186/E-cadherin/EMT pathway. RUNX3 may be recommended as an effective prognostic indicator and therapeutic target for patients with HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18424